Orion Oyj (ORINF)
ORINF Stock Price Chart
Explore Orion Oyj interactive price chart. Choose custom timeframes to analyze ORINF price movements and trends.
ORINF Company Profile
Discover essential business fundamentals and corporate details for Orion Oyj (ORINF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
28 May 2013
Employees
3.94K
Website
https://www.orion.fiCEO
Liisa Hurme
Description
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
ORINF Financial Timeline
Browse a chronological timeline of Orion Oyj corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Feb 2026
Upcoming earnings on 28 Oct 2025
Earnings released on 18 Jul 2025
EPS came in at $0.70 surpassing the estimated $0.61 by +13.93%, while revenue for the quarter reached $490.40M , beating expectations by +13.01%.
Earnings released on 23 Apr 2025
EPS came in at $0.48 surpassing the estimated $0.43 by +12.39%, while revenue for the quarter reached $388.73M , beating expectations by +4.37%.
Earnings released on 25 Feb 2025
EPS came in at $0.54 surpassing the estimated $0.51 by +5.70%, while revenue for the quarter reached $449.82M , beating expectations by +4.53%.
Dividend declared on 25 Feb 2025
A dividend of $0.86 per share was announced, adjusted to $0.86. The dividend will be paid on 23 Oct 2025.
Dividend declared on 25 Feb 2025
A dividend of $0.89 per share was announced, adjusted to $0.96. The dividend was paid on 14 Apr 2025.
Earnings released on 29 Oct 2024
EPS came in at $1.25 surpassing the estimated $1.18 by +5.93%, while revenue for the quarter reached $516.89M , beating expectations by +0.54%.
Earnings released on 8 Aug 2024
EPS came in at $0.40 surpassing the estimated $0.35 by +12.94%, while revenue for the quarter reached $352.25M , beating expectations by +1.88%.
Earnings released on 25 Apr 2024
EPS came in at $0.34 falling short of the estimated $0.34 by -2.47%, while revenue for the quarter reached $331.63M , beating expectations by +1.04%.
Earnings released on 20 Mar 2024
EPS came in at $0.59 surpassing the estimated $0.45 by +29.82%, while revenue for the quarter reached $353.13M , beating expectations by +1.97%.
Dividend declared on 13 Feb 2024
A dividend of $0.88 per share was announced, adjusted to $0.95. The dividend was paid on 23 Oct 2024.
Dividend declared on 13 Feb 2024
A dividend of $0.88 per share was announced, adjusted to $0.95. The dividend was paid on 3 Apr 2024.
Earnings released on 30 Sept 2023
EPS came in at $0.46 surpassing the estimated $0.39 by +19.84%, while revenue for the quarter reached $317.61M , beating expectations by +2.05%.
Earnings released on 30 Jun 2023
EPS came in at $0.28 falling short of the estimated $0.38 by -24.70%, while revenue for the quarter reached $315.82M , missing expectations by -1.17%.
Earnings released on 31 Mar 2023
EPS came in at $0.34 falling short of the estimated $0.35 by -2.33%, while revenue for the quarter reached $302.25M , missing expectations by -2.97%.
Earnings released on 9 Feb 2023
EPS came in at $0.23 falling short of the estimated $0.28 by -17.86%, while revenue for the quarter reached $317.33M , beating expectations by +0.23%.
Dividend declared on 9 Feb 2023
A dividend of $1.74 per share was announced, adjusted to $1.87. The dividend was paid on 31 Mar 2023.
Earnings released on 20 Oct 2022
EPS came in at $1.38 surpassing the estimated $1.32 by +4.55%, while revenue for the quarter reached $480.38M , missing expectations by -0.20%.
Earnings released on 15 Jul 2022
EPS came in at $0.47 surpassing the estimated $0.35 by +34.29%, while revenue for the quarter reached $296.76M , beating expectations by +8.05%.
Earnings released on 28 Apr 2022
EPS came in at $0.41 surpassing the estimated $0.39 by +5.13%, while revenue for the quarter reached $299.32M , beating expectations by +0.92%.
Earnings released on 10 Feb 2022
EPS came in at $0.23 falling short of the estimated $0.28 by -17.86%, while revenue for the quarter reached $313.47M , beating expectations by +3.18%.
Dividend declared on 10 Feb 2022
A dividend of $1.65 per share was announced, adjusted to $1.75. The dividend was paid on 1 Apr 2022.
Earnings released on 20 Oct 2021
EPS came in at $0.32 matching the estimated $0.32, while revenue for the quarter reached $279.61M .
Earnings released on 19 Jul 2021
EPS came in at $0.40 surpassing the estimated $0.35 by +14.29%, while revenue for the quarter reached $302.42M .
Earnings released on 27 Apr 2021
EPS came in at $0.42 surpassing the estimated $0.36 by +16.67%, while revenue for the quarter reached $315.92M .
Earnings released on 9 Feb 2021
EPS came in at $0.18 falling short of the estimated $0.29 by -37.93%, while revenue for the quarter reached $313.21M .
Dividend declared on 9 Feb 2021
A dividend of $1.77 per share was announced, adjusted to $1.75. The dividend was paid on 7 Apr 2021.
Earnings released on 21 Oct 2020
EPS came in at $0.37 surpassing the estimated $0.31 by +19.35%, while revenue for the quarter reached $293.88M .
ORINF Stock Performance
Access detailed ORINF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.